Impressive advances in defining the properties of receptors for the Fc portion of immunoglobulins (FcR) have been made over the past several years. Ligand specificities were systematically analyzed for both human and mouse FcRs that revealed novel receptors for specific IgG subclasses. Expression patterns were redefined using novel specific anti-FcR mAbs that revealed major differences between human and mouse systems. 
Impressive advances in defining the properties of receptors for the Fc portion of immunoglobulins (FcR) have been made over the past several years. Ligand specificities were systematically analyzed for both human and mouse FcRs that revealed novel receptors for specific IgG subclasses. Expression patterns were redefined using novel specific anti-FcR mAbs that revealed major differences between human and mouse systems. 
Advances in Fc␥R ligand specificities and expression

Human Fc␥Rs
The human IgG receptor family consists of several activating receptors (hFc␥RI, hFc␥RIIA, hFc␥RIIC, and hFc␥RIIIA), 1 inhibitory receptor (hFc␥RIIB), 1 receptor with unclear functions (hFc␥RIIIB), 1,2 and 1 receptor (hFcRn) involved in recycling and transport of IgG among other functions 3, 4 (Figure 1 ). Activating hFc␥RI and hFc␥RIIIA requires the association of the FcR␥ subunit (Fcer1g) to be expressed and functional at the cell surface. FcR␥ indeed contains an immunoreceptor tyrosine-based activation motif (ITAM) that, after aggregation of these latter receptors at the cell membrane, is required for cell activation. hFc␥RIIA and hFc␥RIIC possess their own ITAM in their intracellular domain and do not associate with the FcR␥ subunit. 5 hFc␥RIIB possesses an immunoreceptor tyrosine-based inhibition motif (ITIM) in its intracellular domain and negatively regulates cell activation and degranulation, cell proliferation, endocytosis, and phagocytosis when coaggregated to an activating FcR. 6, 7 hFc␥RIIB and hFc␥RIIC share the same extracellular domain, but hFc␥RIIC is expressed by only 20% of persons (FcgR2C-ORF) because of an allelic polymorphism introducing a stop codon in its third exon (FcgR2C-Stop). 8, 9 In 2007, the characterization of the 2 first human Fc␥RIIB/Cspecific mAbs (clone GB3 10 and clone 2B6 11 ) allowed reexamination of the expression patterns of hFc␥RIIB, particularly in FcgR2C-Stop persons.
Published data using human FcR-specific mAbs can be summarized by the following features: hFc␥RI (CD64) is restricted to monocytes/macrophages and dendritic cells (DCs) and, inducibly, expressed on neutrophils 12 and mast cells 13 ; hFc␥RIIA (CD32A) is expressed on all myeloid cells but not on lymphocytes; hFc␥RIIB (CD32B) is highly expressed only on circulating B cells 11 and basophils (L. Cassard, F. Jönsson, S. Arnaud, P.B., M. Daëron, manuscript submitted, October 2011), poorly expressed on 20% of the monocytes and 4% of the neutrophils, 10, 11 and expressed on tissue macrophages and DCs, 11 but not on mast cells 14 ; hFc␥RIIC (CD32C) is expressed on NK cells, 8 monocytes, and neutrophils 9 ; hFc␥RIIIA (CD16A) is expressed on NK cells and monocytes/ macrophages; hFc␥RIIIB (CD16B) is expressed on neutrophils and, as recently demonstrated, on subsets of basophils. 15 These expression patterns highlight that hFc␥RIIA is the only activating IgG receptor constitutively expressed by mast cells, basophils, neutrophils and eosinophils. Importantly, human activating IgG receptors may be negatively regulated by hFc␥RIIB only on B cells and basophils, but not on mast cells, NK cells, and on most neutrophils and monocytes that do not express this inhibitory receptor. Recently, nevertheless, a novel polymorphism affecting the locus encoding human FcRs has been reported that leads to hFc␥RIIB expression on NK cells and has been shown to negatively regulate IgG-induced NK cell activation. 9 Finally, hFcRn is expressed on antigen-presenting cells, monocytes/macrophages, 16 neutrophils, 4 vascular endothelial cells, intestinal epithelial cells, and, importantly, on syncytiotrophoblasts, which allow transfer of IgG from mother to fetus antenatally 17 (Table 1) . hFcRn was reported not only to transport and recycle IgG but also to transport IgG-bound antigens favoring antigen presentation and subsequent immune responses, 3 and to enable phagocytosis of IgG-opsonized bacteria by neutrophils. 4 We have recently reanalyzed the ligand specificity of hFc␥Rs using both Surface Plasmon Resonance on soluble hFc␥Rs (Table  2) and flow cytometry on a collection of transfectants expressing similar levels of hFc␥Rs. 18 Polymorphic variants were included in this analysis when the mutation was in the extracellular domain of the receptors: hFc␥RIIA variants H 131 Table 2) . Polymorphisms within the extracellular domain affected binding properties for only IgG1 and IgG2, and hFc␥RIIA and hFc␥RIIIA, but not hFc␥RIIIB. 18 The identification of receptors for IgG4 is of importance. IgG4 was, indeed, considered a "neutral" IgG isotype because it does not bind complement and was thought not to bind hFc␥Rs. 19 Indeed, IgG4-based therapeutic antibodies have been designed based on this assumption, for example, natalizumab (anti-VLA-4), gemtuzumab (anti-CD33), 20 and TGN1412 (anti-CD28); the 2 latter drugs have now been withdrawn from the market. Notably, hFc␥RI was found to be a high-affinity receptor for IgG4. 18 The capacity of hFc␥RI to bind IgG1, IgG2, and IgG4 with high affinity was proposed to rely on the third extracellular domain (unique to Fc␥RI). 12 However, recent crystallographic data suggest that this capacity is the result of a shorter loop between the F and G ␤-sheets (FG-loop) in the second extracellular domain of hFc␥RI, compared with low-affinity hFc␥Rs. 21 Of note, the high-affinity IgG receptor hFcRn 22 is quite dissimilar from hFc␥RI in that hFcRn binds IgG through the C H 2-C H 3 hinge region of IgG1, IgG2, IgG3, and IgG4 23 only at acidic pH (pH 6-6.5), hFcRn is structurally related to MHC class I molecules and hFcRn expression requires association to ␤ 2 -microglobulin. 17 
Mouse Fc␥Rs
In 2005, the characterization of a novel activating mouse IgG receptor, Fc␥RIV, was reported 24 that subsequently led to a profound reanalysis of mouse FcR ligands and expression patterns. Fc␥RIV exists in rodents (mouse, rat, hamster) 25 and in some nonhuman primates (macaque, gibbon, orangutan) but not in others (gorilla, chimpanzee), and importantly not in humans (J. Lejeune, B. Piégu, P. Gaudray, M. Ohresser, H. Watier, manuscript submitted, April 2012). Fc␥RIV, like the 2 other mouse activating IgG receptors, Fc␥RI and Fc␥RIII, requires the association of the FcR␥ subunit to 
ϩ indicates expression; (ϩ), inducible expression; ϩ/Ϫ, very low percentages or rare subsets express the receptor; Ϫ, no expression; and NA, not analyzed. *In Fcgr2c-ORF persons. 9 †Detectable and functional expression in nonconventional Fcgr2c-Stop persons. 9 be expressed and functional at the cell surface. 5 Fc␥RIV is a high-affinity receptor for mouse IgG2a and IgG2b, as it binds monomers of both IgG subclasses. 26 17 Novel specific mAbs generated against mouse Fc␥Rs have facilitated the examination of the expression pattern of Fc␥RIII and of the newly cloned Fc␥RIV. Reports in wild-type (WT) mice have described Fc␥RI to be restricted to monocyte-derived DCs, 33, 34 Fc␥RIV to be restricted to Ly6C lo monocytes, 35 macrophages, and neutrophils, 26 whereas Fc␥RIIB and Fc␥RIII were shown to be expressed on all myeloid populations 12 ; Fc␥RIIB is also expressed on B cells and Fc␥RIII also on NK and NKT cells. 36 FcRn is expressed on antigen-presenting cells on neutrophils, 4 on splenic monocytes and B cells, 37 on the vascular endothelium, and, during the neonatal period, on epithelial cells of the intestine 17 (Table 3 ). Among the newly described FcR-specific mAbs, blocking mAbs were characterized for Fc␥RIII (clone 275003) 38 and Fc␥RIV (clone 9E9). 24 Fc␥RIIB-specific blocking mAbs (clone K75.325 anti-Ly17.1 haplotype or clone K9.361 anti-Ly17.2 haplotype) were described in the 1980s. 29 However, a Fc␥RI-specific blocking mAb has still not been reported.
Human versus mouse Fc␥Rs
Most human Fc␥Rs bear the same name and CD as mouse Fc␥Rs. They are, however, quite dissimilar in binding abilities and expression pattern. Recent analyses revealed 3 major differences between human and mouse Fc␥Rs binding abilities: (1) all human activating Fc␥Rs bind the major human IgG subclass IgG1, 18 whereas only mouse activating Fc␥R Fc␥RIII binds mouse IgG1 26 ; (2) human inhibitory hFc␥RIIB has a lower affinity for IgG1, IgG2, and IgG3 than all other hFc␥Rs, 18 which is not the case in mice for IgG1 and IgG2b 24 ; and (3) no human Fc␥R binds human IgE, 18 whereas 3 of the 4 mouse Fc␥Rs (Fc␥RIIB, Fc␥RIII, Fc␥RIV) bind mouse IgE. 26 Rooijen, X. Kang, M. Daëron, P.B., manuscript in preparation), human Fc␥RIIA binds mouse IgG1, 2a, and 2b, but not mouse IgG3, and human Fc␥RIIIB does not bind mouse IgG. 38 Notably, human FcRn has no affinity for mouse IgG1, but its low affinity for mouse IgG2a and IgG2b 39 is sufficient to restore a mouse IgG2-dependent autoimmune arthritis in a transgenic mouse model (mice deficient for FcRn and transgenic for hFcRn). 40, 41 Major differences between human Fc␥R expression patterns and that of their mouse homolog also exist: (1) the expression of mouse, but not human, Fc␥RI is restricted to monocyte-derived DCs; (2) the expression of human, but not mouse, Fc␥RIIB is mainly restricted to B cells and basophils; (3) the expression of human Fc␥RIIIA, but not mouse Fc␥RIII, is restricted to NK cells and monocytes/ macrophages; (4) Fc␥RIV exist in mice but not in humans 24, 25 ; and (5) Fc␥RIIA, Fc␥RIIC, and Fc␥RIIIB exist in humans but not in mice. 12 Fc␥R homologs between humans and mice may thus be defined based on expression and ligand binding, rather than on amino acid similarity. Illustrating this concept, when binding IgG, mouse Fc␥RIV was proposed to be a "functional" homolog of human IgG receptors hFc␥RIIIA 24, 42 
Advances in the roles of Fc␥Rs in antibody-mediated pathologies
Several IgG-mediated mouse models of inflammatory disease have been recently used to address the properties of Fc␥Rs in vivo. The identification of mouse Fc␥RIV as a novel activating IgG receptor 24 led, indeed, to readdress the contributions of mouse activating IgG receptors Fc␥RI and Fc␥RIII. Data are summarized in the next 2 sections from models of inflammatory diseases that highlight the contribution of this novel IgG receptor in inflammatory reactions.
Data using Fc␥R-deficient mice
Mice deficient for the FcR␥ subunit (FcR␥ Ϫ/Ϫ mice) that is required for all activating Fc␥Rs to be expressed and functional were reported as early as 1994. 43 These mice lack expression of Fc␥RI, Fc␥RIII, and Fc␥RIV (and Fc⑀RI) 1 but present also multiple non-FcR-related abnormalities. The FcR␥-chain is, indeed, also required for the expression of macrophage-inducible C-type lectin (Mincle) 44 and osteoclast-associated receptor (OSCAR), 45 and contributes to the signal transduction of several other molecules. Fc␥RIIB Ϫ/Ϫ mice were reported in 1996, 46 Fc␥RIII Ϫ/Ϫ mice in 1996 47 and 1999, 48 [61] [62] [63] [64] have also been reported to be involved/mandatory. Indeed, an increasing number of reports have revealed that activating Fc␥RIII mediates the anti-inflammatory effects of intravenous immunoglobulin in experimental thrombocytopenia when expressed on DCs 61 or on macrophages, 62 in allergic airway inflammation when expressed on NKT cells, 63 and in a nonimmune inflammation model of obstructive nephropathy. 64 Using knockout mice for a particular FcR was for a long time considered the standard approach to address the function of a particular Fc␥R in vivo (ie, by studying the effect of its absence). Recently, however, the generation of multiple FcR-knockout mice has enabled the study of a particular FcR in the absence of most/all other FcRs. Fc␥RI/IIB/III-triple knockout (3KO) mice, lacking 3 of the 4 mouse Fc␥Rs, were indeed described to retain the ability to develop collagen-induced arthritis after immunization with bovine 
*Monocyte-derived DCs, but not conventional DCs. 34 †On splenic B cells only. 37 collagen type II in Freund adjuvant. 65 Because these mice express only Fc␥RIV as an activating IgG receptor, it was deduced that Fc␥RIV contributes to collagen-induced arthritis. These mice, nevertheless, express the high-affinity IgE receptor Fc⑀RI that may also contribute to collagen-induced arthritis, as immunizations in Freund adjuvant leads to antigen-specific IgG but also IgE production. 38 Fc␥RI/IIB/IIIA Fc⑀RI/II-quintuple knockout mice, which do not express Fc␥Rs or Fc⑀Rs other than Fc␥RIV (5KO, also known as "Fc␥RIV-only"), were subsequently generated and have circumvented this potential issue. Using "Fc␥RIV-only" mice we reported that Fc␥RIV induced arthritic inflammation in the passive K/BxN model of arthritis 66 in the presence of IgG2-immune complexes. 41 These results are in agreement with those obtained when inducing collagen-induced arthritis in 3KO mice. 65 "Fc␥RIV-only" mice also developed lung inflammation after activation of alveolar macrophages in the presence of IgE-immune complexes, 26 and experimental thrombocytopenia induced by antiplatelet mouse IgG2a mAbs. 38 Furthermore, using Fc␥RI/IIB/III Fc⑀RI/II FcRnsextuple knockout (6KO) mice, we have reported that Fc␥RIV-dependent induction of K/BxN arthritis requires FcRn, probably to transport pathogenic IgG2 antibodies to the joints and to protect these antibodies from degradation. 41 These analyses using "Fc␥RIV-only" mice, have not yet been performed using "Fc␥RI-only" or "Fc␥RIII-only" mice to evaluate their contribution to the induction of inflammatory models. "Fc␥RIII-only" mice may not be particularly worthy to generate because Fc␥RIII is the only activating IgG receptor that binds IgG1. Disease models that rely on pathogenic antibodies of the IgG1 subclass depend therefore on Fc␥RIII. "Fc␥RI-only" mice may be worth generating because Fc␥RI, like Fc␥RIV, binds mouse IgG2a and IgG2b. 24, 26 Fc␥RI and Fc␥RIV may play redundant roles that may explain why studies using Fc␥RI Ϫ/Ϫ mice have not reported a contribution of Fc␥RI to K/BxN arthritis 56 or to experimental thrombocytopenia after injections of IgG2b antiplatelet antibodies for example. 24 "Fc␥RI-only" mice may, however, reveal the contribution of Fc␥RI to these and/or other models that may be undetectable when Fc␥RIV is coexpressed with Fc␥RI. Of note, Fc␥RI is reported to be expressed in unchallenged mice only on DCs 33 and, among DC subsets, specifically on monocytederived DC subsets, as recently shown in the muscle tissue and its draining lymph nodes. 34 
Data using anti-mouse Fc␥R blocking mAbs
Using specific blocking mAbs has proven efficient to analyze the properties of a particular FcR in vivo in WT mice without necessitating simple or multiple Fc␥R knockouts. Specific in vivo blocking abilities of mAbs were, indeed, described for Fc␥RIIB in 2001, 29, 59 for Fc␥RIII in 2011, 38, 41 and for Fc␥RIV in 2005. 24 Unfortunately, no blocking mAb exists for Fc␥RI. WT mice treated with anti-Fc␥RIII mAbs have shown that Fc␥RIII contributes to K/BxN arthritis, 41 to active systemic anaphylaxis (ASA), and is mandatory for IgG1-induced PSA. 38 WT mice treated with antiFc␥RIV mAbs have revealed that Fc␥RIV contributes to experimental thrombocytopenia, 24 K/BxN arthritis, 41 and ASA and is mandatory for IgG2b-induced PSA. 38 WT mice treated with a combination of anti-Fc␥RIII and anti-Fc␥RIV mAbs have revealed that these receptors are, together, responsible for K/BxN arthritis 41 and for ASA. 38 That these receptors are responsible for the induction of K/BxN arthritis is in agreement with previous reports using knockout mice. 52,55, 56 However, that these receptors are responsible for the induction of ASA is unexpected. Altogether, these results in WT mice validate and extend the results obtained using single or multiple FcR-deficient mice. Therefore, using specific blocking anti-FcR mAbs in WT mice will certainly become the method of choice to study FcR properties in vivo.
Data using FcR-humanized mice
Studying human FcRs in vivo constitutes a major challenge that many have attempted by generating human FcR-transgenic mice. Human Fc␥RI tg mice were reported in 1996, 67 hFc␥RIIA tg mice in 1999, 68 hFc␥RIIB tg in 2011, 69 hFc␥RIIIA tg and hFc␥RIIIB tg mice in 1996, 70 and hFcRn tg in 2003. 51 hFc␥RIIC tg mice have not yet been generated. hFc␥RIIA tg and hFc␥RIIIB tg mice closely recapitulated their respective expression patterns in humans. Unfortunately, hFc␥RI is constitutively expressed on neutrophils in hFc␥RI tg mice, whereas an inducible expression is reported on human neutrophils. 71 hFc␥RIIIA and hFc␥RIIIB have recently been reported to be both expressed on spleen and circulating DCs, and hFc␥RIIIA on eosinophils from hFc␥RIIIA tg hFc␥RIIIB tg mice 72 but are not expressed on these cell populations in humans. hFc␥RIIB tg mice have high hFc␥RIIB expression on more than 90% mouse monocytes and granulocytes compared with the poor expression on minor fractions of these cell types reported in humans. 11 Crossing these transgenic mice together resulted in a mouse model expressing multiple hFc␥Rs (ie, hFc␥RI/IIA/IIB/IIIA/ IIIB, except hFc␥RIIC and hFcRn) that conserved the original expression patterns of these human transgenes and, unfortunately, also their abnormal expression on several cell populations. 72 The in vivo properties of these human Fc␥Rs can, nevertheless, be studied in these transgenic mice, but conclusions on their contribution to disease and therapy models are thus to be drawn carefully to remain meaningful. Another difficulty to analyze the contribution of these receptors to disease and therapy models in FcR-humanized mice comes from the cross-binding of human and mouse IgG to human and mouse FcRs (detailed in "Advances in Fc␥R ligand specificities and expression"). This cross-binding can potentially lead to a competition in vivo for IgG binding between the transgenic human Fc␥R and the endogenous mouse Fc␥R. This phenomenon may also induce the aggregation of receptors originating from different species, which result in artifactual situations. The expression of a supplementary IgG receptor in WT mice, as it is the case when a transgene encodes for a human Fc␥R, may also lead to adverse reactions. Studies using mice transgenic for hFc␥RIIA on a WT background, indeed, reported spontaneous autoimmune diseases (ie, pneumonitis, glomerulonephritis, and rheumatoid arthritis). 73 The expression of hFc␥RI on a WT mouse background, however, was reported to not lead to adverse reactions. Why a human Fc␥RIIA encoding transgene, but not a human Fc␥RI encoding transgene is pathogenic when expressed in vivo in WT mice remains unanswered but may relate to their different expression pattern (Table 1 ) and/or cross-binding of mouse IgG (detailed in "Advances in Fc␥R ligand specificities and expression"). hFc␥RI tg mice have revealed that hFc␥RI enables antigen targeting to DCs for enhanced protective immunity 67 and IgG-dependent protection against malaria infection. 74 In most cases, however, the analysis of the properties of human FcRs in vivo in inflammatory models of disease requires that the transgenes encoding human FcRs are expressed in mice deficient for endogenous FcRs to avoid competition for ligands or artifacts.
For example, hFc␥RIIA, which does not require the FcR␥ subunit to be expressed and functional (Figure 1 ), was expressed in FcR␥ Ϫ/Ϫ mice that lack expression of endogenous activating Fc␥Rs (Fc␥RI, Fc␥RIII, and Fc␥RIV). These hFc␥RIIA tg FcR␥ Ϫ/Ϫ mice have revealed that hFc␥RIIA expression was sufficient to restore IgG-dependent experimental autoimmune thrombocytopenia, 68 rheumatoid arthritis, 75 and allergic reactions and lung inflammation 76 in resistant mice (detailed in "Role of Fc␥R ϩ cells in Ab-induced pathologies [eg, arthritis and anaphylaxis]"). The same strategy may be used for the analysis of hFc␥RIIB, hFc␥RIIC, or hFc␥RIIIB that do not require the FcR␥ subunit, but not for the analysis of hFc␥RI and hFc␥RIIIA that require the FcR␥ subunit to be expressed and functional. As an alternative to the FcR␥ Ϫ/Ϫ background, we have recently used the multiple FcR-deficient mice we generated (5KO also known as Fc␥RI/IIB/III Fc⑀RI/II-deficient mice) 26 to express and analyze in vivo hFc␥RIIA 76 or hFc␥RI (D. A. Mancardi, M. F. Albanesi, F. Jönsson, B. Iannascoli, N. V. Rooijen, X. Kang, M. Daëron, P.B., manuscript in preparation) in disease and therapy models. Of note, these mice still express endogenous Fc␥RIV that may be blocked in vivo using specific blocking mAbs. The recent generation of mice deficient for all endogenous mouse Fc␥Rs and expressing multiple hFc␥Rs (hFc␥RI/IIA/IIB/IIIA/IIIB) 72 allowed to study their properties without the interference of endogenous Fc␥Rs or usage of blocking mAbs. These mice confirmed, indeed, the activities reported previously in mice expressing a single hFc␥R transgene in models of thrombocytopenia, B-cell depletion, and PSA. 68, 69, 76 Finally, hFcRn was expressed in FcRn Ϫ/Ϫ mice and revealed that hFcRn prolongs the life span of human IgG 40 and albumin, 51 enables capture and processing of luminal IgG-bound antigens favoring the adaptive immune response, 3 and restores K/BxN arthritis in resistant FcRn Ϫ/Ϫ mice. 41 Most of these analyses were, however, performed in mice expressing only one human IgG receptor and do not recapitulate the complexity of their interactions in the human system. A mouse model expressing the full array of hFc␥Rs and hFcRn, and lacking all endogenous FcRs, may thus prove an invaluable tool to study human IgG receptor biology, provided that the expression pattern of the human FcRs in transgenic mice reproduces their expression pattern in humans.
Role of Fc␥R ؉ cells in Ab-induced pathologies (eg, arthritis and anaphylaxis)
Many attempts have recently been made to determine the cell population(s) responsible for the in vivo properties of a specific FcR in a specific disease model. In this aim, mice deficient for a given cell population are compared with WT mice, or cell-specific depletion is achieved using depleting mAbs or compounds. To illustrate how the recent description of the expression patterns of mouse and human Fc␥Rs, coupled with Fc␥R-blocking antibodies, cell-depletion experiments, and multiple Fc␥R-deficient mice, have helped to define the role of FcR-expressing cell populations in disease models, the following 2 sections describe reports on arthritis and anaphylaxis models that have, unexpectedly, demonstrated a major contribution of neutrophils to disease induction.
Arthritis
These approaches described herein were used to analyze the requirement for specific cell subsets in the development of the K/BxN passive arthritis model, which relies on the injection of autoantibody-containing sera from KRN tg C57BL/6 ϫ NOD F1 mice. 77 This model was reported to be abrogated in WT mice depleted of monocytes/macrophages 78 or depleted of neutrophils. 79 This latter result was confirmed by the resistance of Gfi-1 Ϫ/Ϫ mice, which lack mature neutrophils, to develop K/BxN arthritis. 80 Further supporting the essential role of neutrophils in K/BxN arthritis, deletion of Syk specifically in neutrophils has been reported to block disease development. 81 The contribution of mast cells in this arthritis model, which had originally been suggested by the resistance of mast cell-deficient W/W v mice 82 to develop pathology, has since come under question by our work 41 and others 81, 83, 84 using mast cell-deficient W sh /W sh mice or Cremediated mast cell ablation. Resistance of W/W v mice to arthritis may indeed rely on the neutropenic state of these mice rather than on their mast cell deficiency, as suggested from another arthritis model. 85 The finding that K/BxN arthritis requires monocytes/ macrophages and neutrophils, but does not require mast cells, is in agreement with results obtained using multiple Fc␥R-deficient mice, such as the 3KO (Fc␥RI/IIB/III-deficient) mice 65 or 5KO (Fc␥RI/IIB/III Fc⑀RI/II-deficient, also known as "Fc␥RIV-only") mice that develop K/BxN arthritis. Indeed, in these mice, K/BxN arthritis was dependent on Fc␥RIV, 41 and Fc␥RIV is expressed only on monocytes, macrophages and neutrophils. 26 Similar results have been reported in a model of collagen-induced arthritis, 65 supporting the conclusion that mast cells are not mandatory but may contribute to arthritis in these mouse models. Furthermore, results obtained using human FcR-transgenic mice support these results, as mast cell-deficient hFc␥RIIA tg mice (F. Jönsson, unpublished data, September 2011) and hFc␥RI tg mice (D. A. Mancardi, M. F. Albanesi, F. Jönsson, B. Iannascoli, N. V. Roeijen, X. Kang, M. Daëron, P.B., manuscript in preparation) develop K/BxN arthritis. In these latter mice, K/BxN arthritis was dependent on hFc␥RI, and the expression of hFc␥RI on effector cells was restricted to monocytes/macrophages and neutrophils. Of note, the deficiency in FcRn was reported to protect mice from experimental arthritis, 58 and expressing human FcRn restored K/BxN arthritis in FcRn-deficient mice. 41 The FcRn-expressing cell subset that is responsible for disease induction has unfortunately not been identified yet, but the recent generation of conditional FcRndeficient mice 37 might enable investigators to address this question.
Anaphylaxis
Anaphylaxis is a hyperacute allergic reaction that can have fatal consequences. The current paradigm states that anaphylaxis is an immediate hypersensitivity reaction to an allergen/antigen mediated by IgE, resulting in the release of granular mediators by mast cells and basophils in patients sensitized to a particular allergen/ antigen. The FcRs and/or cell subsets that were identified to be responsible for anaphylaxis induction are, however, different depending on the experimental protocol used.
IgE-induced PSA. IgE-induced PSA is elicited by injecting WT mice systemically with IgE antibodies 24 to 48 hours before an intravenous challenge with specific antigen. IgE-induced PSA was abrogated in mice deficient for Fc⑀RI, the high-affinity IgE receptor expressed by mast cells and basophils. 86 Notably, it was abrogated in mast cell-deficient W/W v mice 54 but not in basophildepleted mice. 87 It was also abrogated in histidine decarboxylasedeficient mice, which lack histamine, 88 and in mice injected with histamine receptor antagonists. 89 These findings demonstrate the mandatory role of mast cells, Fc⑀RI, and histamine in IgE-induced PSA (Figure 3) .
IgG-induced PSA. IgG-induced PSA is elicited by injecting mice systemically with IgG antibodies 2 to 3 hours before an intravenous challenge with a specific antigen. Alternatively, preformed IgG immune complexes can be injected intravenously.
Similar symptoms, with comparable kinetics, develop during IgEand IgG-induced PSA. Passively administered IgG1-immune complexes induce anaphylaxis (IgG1-induced PSA) that relied exclusively on Fc␥RIII. 38 IgG1-induced PSA was reported to be negatively regulated by inhibitory Fc␥RIIB. 48 Indeed, Fc␥RIII and Fc␥RIIB are the only receptors for mouse IgG1 (Figure 2) . Surprisingly, IgG1-induced PSA was not abrogated in mast celldeficient mice. 54 The depletion of monocytes/macrophages, NK cells, or neutrophils had no effect, whereas basophil depletion abrogated IgG1-induced PSA. 87 Basophil-deficient mice, however, develop IgG1-induced PSA, 90 which is in contradiction with the result obtained after depletion of basophils. Whatever the cell subset involved, the activation of this subset during IgG1-induced PSA should lead to the production of platelet-activating factor (PAF). Indeed, PAF was reported to be responsible for IgG1-induced PSA. 87 Passively administered IgG2b-IC also induce anaphylaxis (IgG2b-induced PSA) that relied exclusively on Fc␥RIV. 38 Surprisingly, the depletion of neutrophils was sufficient to abolish IgG2b-induced PSA. IgG2b-induced PSA therefore relies on Fc␥RIV and neutrophils and is correlated with elevated serum levels of PAF (Figure 3) . Passively administered immune complexes made of antigen-specific polyclonal IgG (pIgG) antibodies and antigen also induce anaphylaxis (pIgG-induced PSA). pIgG are essentially of the IgG1 and IgG2a/b subclasses. One may therefore consider that pIgG-induced PSA recapitulates IgG1-and IgG2b-induced PSA. pIgG-induced PSA was reduced after blocking of Fc␥RIV and was abolished after depletion of neutrophils. 38 Therefore, pIgG-induced PSA relies on neutrophils and at least partially on Fc␥RIV.
ASA. ASA is elicited by injection of antigen-immunized mice with the same antigen. ASA therefore resemble human anaphylaxis that arises in patients sensitized against a specific antigen/allergen. Unexpectedly, results obtained in ASA models have not correlated well with most results obtained in passive anaphylaxis models. Indeed, neither IgE, 91 Fc⑀RI, 54 mast cells, nor basophils 86, 87 are mandatory for the induction of ASA. ASA even occurred in the absence of both mast cells and basophils. 87 In a model of ASA induced by an intravenous injection of goat IgG in mice immunized with goat IgG anti-mouse IgD, the injection of anti-Fc␥RIIB/III blocking mAb 2.4G2 abolished the reaction, suggesting that Fc␥RIII is mandatory to induce ASA in this model (GaMD-ASA). Neither mast cells, granulocytes, nor platelets were required, but, surprisingly, blockade of monocyte/macrophage activation abolished the reaction. 92 Activation of monocytes/macrophages can result in PAF release 93 ; indeed, PAF-R antagonists abolish GaMD-ASA. 92 We, however, recently demonstrated that monocyte/ macrophages do not contribute to ASA using a different model in which mice are immunized with BSA in Freund adjuvant and challenged with BSA 38 (BSA-ASA). Unexpectedly, neutrophils (predominantly) and basophils (modestly) contributed to the shock. As expected, 54 ASA occurred in WT mice, but not in FcR␥ Ϫ/Ϫ mice that express no activating IgE and IgG receptors. ASA was abolished in mice injected with anti-Fc␥RIII and anti-Fc␥RIV mAbs. Even though antigen-specific IgG and antigen-specific IgE are present in these mice at the time of disease induction, the IgG receptors Fc␥RIII and Fc␥RIV are responsible for ASA induction. In agreement with the results obtained in GaMD-ASA, 92 PAF receptor antagonists strongly inhibited BSA-ASA. 38 Altogether, these data propose on the one hand that macrophages activated after Fc␥RIII engagement release PAF that is responsible for GaMD-ASA and, on the other hand, that neutrophils (and basophils) activated after Fc␥RIII and Fc␥RIV engagement release PAF that is responsible for BSA-ASA (Figure 3) . Importantly, the transfer of human neutrophils restored BSA-ASA in anaphylaxisresistant mice, 38 suggesting a role for neutrophils in human anaphylaxis. Supporting this hypothesis, 95% of human neutrophils express only activating IgG receptors (hFc␥RIIA and, inducibly, hFc␥RI) and, in atopic persons, IgE receptors (Fc⑀RI), 94 but no inhibitory IgG receptor (Fc␥RIIB). 11 Human neutrophils are thus prone to activation after encounter of immune complexes.
Anaphylaxis in FcR-humanized mice. In 1996, the generation of the first human FcR transgenic mice allowed the investigation of its role in PSA. Indeed, IgE-PSA was restored in mice transgenic for hFc⑀RI and deficient for mouse Fc⑀RI, but not in mice that did not carry the human transgene. 95 This pioneer work demonstrated that anaphylaxis could be reconstituted in an "FcR-humanized" mouse. Taking advantage of the cross-binding of mouse IgE to hFc⑀RI, the authors injected antigen-specific mouse IgE that bound to hFc⑀RI in vivo before antigen challenge to induce anaphylaxis. The responsible cell population was, however, not identified. Until recently, no other report has investigated the role, if any, of human IgG receptors in anaphylaxis using hFc␥R-transgenic or knock-in mice. We investigated the ability of hFc␥RIIA to induce anaphylaxis in hFc␥RIIA tg mice for 2 reasons: (1) human neutrophils can restore anaphylaxis when transferred to anaphylaxis-resistant mice 38 ; and (2) human neutrophils constitutively express only one activating IgG receptor, hFc␥RIIA. Cross-binding of mouse IgG1, IgG2a, and IgG2b subclasses to hFc␥RIIA 38 allowed testing of active systemic anaphylaxis (BSA-ASA) in hFc␥RIIA tg FcR␥ Ϫ/Ϫ mice but also PSA and PCA using mouse or human immune complexes. hFc␥RIIA could induce fatal ASA, PSA, and PCA, which were abolished by specific anti-hFc␥RIIA blocking mAbs. hFc␥RIIA expressed in transgenic mice can therefore replace mouse IgG receptors Fc␥RIII and Fc␥RIV in the induction of anaphylaxis. hFc␥RIIA-dependent PCA required mast cells, 76 in agreement with Fc␥RIII-dependent PCA 47 and Fc⑀RI-dependent PCA, 96 which also required mast cells. The induction of hFc␥RIIA-dependent PSA required neutrophils and monocyte/macrophages but did not require mast cells or basophils. These results support and strengthen results obtained on the contribution of neutrophils and monocytes/ macrophages to systemic anaphylaxis in WT mice. 38, 92 The mediators responsible for the induction of hFc␥RIIA-dependent anaphylaxis have not been identified yet. hFc␥RIIA engagement on human monocytes and neutrophils has been reported to lead to PAF release 38 among that of several anaphylactogenic mediators. 93 PAF may therefore contribute to hFc␥RIIA-dependent anaphylaxis.
Final considerations
The field of Fc receptors has increased in complexity after the identification of a novel IgG receptor in 2005. 24 The generation of knockouts for each mouse FcR and of specific (blocking) anti-FcR mAbs, nevertheless, enabled to establish a refined picture of FcR properties and functions in vivo. Models of arthritis, thrombocytopenia, and anaphylaxis have benefited largely from these advances, and more disease models are currently being similarly analyzed. Blocking Fc␥Rs in vivo using specific mAbs will certainly become the experimental approach of choice to address their function in vivo, as it avoids genetic background issues and phenotypic variations among knockouts. In this line of reasoning, experiments using blocking anti-Fc␥RIIB mAbs in vivo may enable to determine the exact contribution of this inhibitory receptor to experimental disease models. Indeed, Fc␥RIIB Ϫ/Ϫ mice were reported to develop myeloproliferation, hypergammaglobulinemia, and autoantibodies leading to strain-specific spontaneous autoimmune diseases. 7, 97 These alterations may contribute to render these mice hypersensitive to experimental models of disease without a direct involvement of Fc␥RIIB during their induction phase.
Like mouse IgE receptor Fc⑀RI and mouse IgG receptors Fc␥RIII and Fc␥RIV, human IgE receptor hFc⑀RI and human IgG receptor hFc␥RIIA are sufficient to trigger IgE-and IgG-induced systemic anaphylaxis, respectively, when expressed in mice. 76, 95 Previous studies demonstrated that hFc␥RIIA is also sufficient to induce experimental thrombocytopenia 68 and arthritis. 73, 75 All these results, however, have been obtained in mice expressing only one hFcR, in the absence of the inhibitory hFc␥RIIB, and in the absence of other activating hFc␥Rs or hFcRn that may regulate or contribute to disease induction/progression. If other human IgG receptors play a role in these diseases in humans, other cell types than those identified so far may contribute to, or even be responsible for, their induction. Illustrating this view, FcRn was reported to be expressed more widely than expected (ie, also on monocytes/macrophages and neutrophils; Tables 1 and 3 ). In addition, the functions of FcRn were reported to compose also antigen uptake and processing by DCs 17, 32 and phagocytosis of IgG-opsonized bacteria by neutrophils. 4 hFcRn might therefore contribute to more models of disease (or therapy) than initially thought and should be studied in vivo when coexpressed with hFc␥Rs. Another example is hFc␥RIIIB, which has been reported to be expressed not only on neutrophils, but also on basophils. 15 hFc␥RIIIB has been recently reported to play specialized roles on neutrophils, different from those played by hFc␥RIIA. 2 Creating mouse models expressing multiple or, preferably, all hFcRs (with the same expression pattern as that found in humans) may be a necessity to comprehend their role in disease induction/modulation, and thereby of the cells expressing them. The recent report by Smith et al using a model of mice expressing multiple hFc␥Rs 72 opens the way to performing these analyses. More efforts, however, will be necessary to obtain mice whose expression patterns of hFc␥Rs fully reproduce that found in humans, in particular on DCs and effector myeloid populations.
Finally, data published on different models of systemic anaphylaxis compile in a rather complicated picture on the various cell types, antibody receptors, and mediators involved (Figure 3) . That neither mast cells nor IgE, but rather neutrophils, monocytes/ macrophages, and IgG, concur to models of ASA is unexpected and opens novel areas of research in human anaphylaxis. [98] [99] [100] Noticeably, neutrophils not only contribute to ASA, they are also responsible for 2 models of IgG-induced PSA 38 in WT mice. Both monocytes/macrophages and neutrophils also contribute to PSA induced by human IgG receptor Fc␥RIIA. 76 This receptor is expressed by human neutrophils that can induce anaphylaxis when transferred in resistant mice and that are the major PAF-producing cell population. 93 Therefore, that PAF and, to a minor extent, histamine are responsible for ASA calls to reevaluate PAF contribution in anaphylaxis based on the findings summarized in this review. Supporting a role for PAF in anaphylactic reactions in the clinic, serum PAF concentration was shown to correlate with the severity of anaphylactic shock. 101 Of note, one may consider only results obtained with models of ASA as human anaphylaxis is essentially active (ie, allergen-sensitized persons encountering that allergen). Passive cases of anaphylaxis may nevertheless occur, for example, after transfusion or organ transplantation from sensitized donors, or after therapeutic antibody treatment. 
